Townsquare Capital LLC Cuts Stock Holdings in Icon Plc (NASDAQ:ICLR)

Townsquare Capital LLC decreased its stake in shares of Icon Plc (NASDAQ:ICLR) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,072 shares of the medical research company’s stock after selling 465 shares during the period. Townsquare Capital LLC’s holdings in Icon were worth $474,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Victory Capital Management Inc. boosted its position in shares of Icon by 2.7% during the second quarter. Victory Capital Management Inc. now owns 16,214 shares of the medical research company’s stock valued at $2,496,000 after buying an additional 421 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Icon by 30.9% during the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after buying an additional 77 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Icon during the second quarter valued at approximately $295,000. D. E. Shaw & Co. Inc. boosted its position in shares of Icon by 7.4% during the second quarter. D. E. Shaw & Co. Inc. now owns 372,219 shares of the medical research company’s stock valued at $57,311,000 after buying an additional 25,723 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Icon by 571.2% during the second quarter. Marshall Wace LLP now owns 74,304 shares of the medical research company’s stock valued at $11,440,000 after buying an additional 63,233 shares during the last quarter. 83.37% of the stock is currently owned by institutional investors.

ICLR stock traded down $1.25 during midday trading on Wednesday, hitting $152.55. The company’s stock had a trading volume of 9,119 shares, compared to its average volume of 188,393. The stock’s 50-day moving average price is $154.17 and its 200 day moving average price is $145.38. The company has a quick ratio of 2.07, a current ratio of 2.07 and a debt-to-equity ratio of 0.28. Icon Plc has a 1 year low of $118.10 and a 1 year high of $165.13. The stock has a market cap of $8.35 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 2.12 and a beta of 0.63.



Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.01. Icon had a return on equity of 25.02% and a net margin of 13.05%. The business had revenue of $695.14 million for the quarter, compared to analysts’ expectations of $693.56 million. During the same quarter in the previous year, the firm earned $1.51 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. As a group, equities analysts forecast that Icon Plc will post 6.88 earnings per share for the current fiscal year.

Several research firms have weighed in on ICLR. BidaskClub raised Icon from a “hold” rating to a “buy” rating in a research report on Tuesday. KeyCorp boosted their price objective on Icon from $157.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Mizuho boosted their price objective on Icon from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Zacks Investment Research cut Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, September 18th. Finally, ValuEngine cut Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, September 11th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Icon currently has a consensus rating of “Buy” and a consensus target price of $165.29.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: Using the New Google Finance Tool

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.